Company profile for Cytoki Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Cytoki Pharma (Cytoki) is a clinical-stage biotechnology company at the forefront of developing innovative therapies that leverage the natural biology of IL-22. Our focus is on treating metabolic diseases, such as obesity and type 2 diabetes, as well as conditions involving epithelial injury, like inflammatory bowel disease. We are advancing our lead candidate, CK-0045, a long-acting IL-22 analogue, toward Phase 2 clinical tri...
Cytoki Pharma (Cytoki) is a clinical-stage biotechnology company at the forefront of developing innovative therapies that leverage the natural biology of IL-22. Our focus is on treating metabolic diseases, such as obesity and type 2 diabetes, as well as conditions involving epithelial injury, like inflammatory bowel disease. We are advancing our lead candidate, CK-0045, a long-acting IL-22 analogue, toward Phase 2 clinical trials. CK-0045 is designed to address the needs of individuals with cardiometabolic diseases by promoting sustained disease modification through effective weight management and additional independent metabolic benefits.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Denmark
Address
Address
Vandtårnsvej 77 DK-2860 Søborg
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/cytoki-pharma-highlights-data-reinforcing-therapeutic-potential-of-lipidated-il-22-for-ibd-in-digestive-diseases-and-sciences-publication-302447688.html

PR NEWSWIRE
08 May 2025

https://www.prnewswire.com/news-releases/cytoki-pharma-announces-first-patient-dosed-in-phase-2-study-of-ck-0045-in-obesity-and-type-2-diabetes-302294879.html

PR NEWSWIRE
04 Nov 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty